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New Technology Add-On Payment
(NTAP) for Viz LVO: a win for stroke care

patients, when the hospital uses Viz LVO
the NTAP will help to defray costs with
an additional payment, up to $1040.

Ameer E Hassan  

Why this is a big deal for stroke

INTRODUCTION

The Centers for Medicare and Medicaid
Services (CMS) recently granted a New
Technology Add-on Payment (NTAP) for
Viz ContaCT (Viz LVO) by V
 iz.ai, Inc, an
applied artificial intelligence healthcare
company.1 This is the first time CMS has
reimbursed an artificial intelligence (AI)-
based software using this designation. It
applies to V
 iz.
ai’s acute ischemic stroke
product, Viz LVO, officially known as Viz
ContaCT, under which the ICD-10 Procedure Coding System (ICD-10-PCS) procedure code 4A03×5D was established.
Viz ContaCT is an AI-based system that
creates a parallel alert system whenever it
detects a large vessel occlusion (LVO) on
a computed tomography angiogram. The
images are viewable on a mobile application which combines HIPAA (Health
Insurance Portability and Accountability
Act)-compliant group messaging functionality with a mobile PACS Viewer. Users can
view the images, make triage decisions,
and communicate with other members of
the care team through chat functionality.
Beyond the specific designation, this
reaching implicadecision may have far-
tions for stroke care and for reimbursement of AI-enabled applications.

What is NTAP?

At a national level, reimbursement is how
health care incentivizes helping patients.
Medicare pays for a patient’s hospital
stay according to the Inpatient Prospective Payment System (IPPS) under a single
bundled payment, which includes all
costs. These payments are captured under
the Medicare Severity Diagnosis-
Related
Group (MS-
DRG) system. While the
MS-DRG rates are updated annually, the
payments are based on Medicare claims
data accrued over a 2 to 3 year period.
The result is that payments lag behind true
costs, particularly for care using new and
expensive technologies.2
Introduced in 2001, the CMS NTAP
program was created by Congress to help
close this gap and support timely access
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to innovative therapies for the Medicare
population. For technologies accepted
under this program, CMS provides an
additional payment to hospitals above
the standard MS-DRG payment amount.
There is an application, review, and
approval process for the NTAP program.
There are three criteria for NTAP:
►► Newness—the technology must be
novel, that is, <3 years old. Typically
this excludes Food and Drug Administration (FDA) 510 k clearances, as
by definition, these are predicated on
another technology
►► Cost—the
technology
is
not
adequately covered under the existing
MS-DRG
►► Substantial clinical improvement—the
technology must prove to CMS that it
provides a substantial clinical advantage over other available technologies,
typically in the form of improved
patient outcomes.
NTAPs are granted based on evidence
submitted with respect to specific products. Other AI companies can submit an
application to CMS demonstrating they
also meet the above criteria, for consideration in a future IPPS NTAP.3

How the Viz.ai NTAP works

In 2019, CMS revised its rules around
reimbursement using the NTAP program,
agreeing with concerns that capping
the payment at the 50% rate may not
adequately support healthcare innovations. In response, CMS increased
payment to 65% of the lesser of (1) the
cost of the new medical service or technology or (2) the amount by which the
costs of the case exceed the standard DRG
payment.4 For the Viz.ai NTAP code, the
additional payment is capped at $1040.
To qualify, a patient must be a Medicare patient with a suspected stroke,
and the estimated cost must exceed the
Medicare reimbursement. As the name
suggests, the payment is added on to
the DRG payment to the hospital for a
qualifying patient, so only applies if the
patient is admitted. In my institution,
Medicare patients account for approximately 51% of our code strokes, and
nationwide approximately 45% of these
patients have an estimated cost greater
than the DRG payment.5 For these
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Given the current revenue climate, a $1040
reimbursement per patient may seem high.
In approving NTAP for Viz LVO, CMS
recognized the clinical benefit of Viz LVO
in the management of patients admitted
with stroke. Thrombectomy has been
proven to be a highly effective treatment
for acute ischemic stroke, and we know
that patients do significantly better the
sooner they are treated.6 It has been estimated that in each minute of an ongoing
stroke, 1.9 million neurons, 14 billion
synapses, and 12 km (7.5 miles) of myelinated fibers are destroyed and that the
ischemic brain loses neurons at an hourly
rate equivalent to 3.6 years of normal
aging.7 8 Data from the Highly Effective
Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaborative suggests that every minute delay
results in a loss of 4 days of disability-free
life.9 Clearly, delays in stroke care result
in significant negative outcomes both for
patients and for the financial well-being of
the healthcare system.
Cost-
benefit analysis of thrombectomy yields similarly striking results:
achieving expanded treatment in cerebral ischemia 3 (eTICI 3) over eTICI 2b
reperfusion resulted on average in 1.31
incremental quality-adjusted life-years
(QALYs) as well as healthcare and societal cost savings of $10 327 and $20 224
per patient, respectively. An estimated
$21 million and $36.8 million for the US
healthcare system and society, respectively,
could be saved by a 10% increase in the
eTICI 2/3 reperfusion rate of all endovascular thrombectomy-treated patients with
stroke.10
The median loss in net monetary benefit
of thrombectomy per minute was calculated to be $1059, and saving 10 min
on average across the USA would save
$249 million annually.9 Implementation
of Viz LVO has been demonstrated to save
66 min on average,11 suggesting a significant return on investment for CMS.
The intent of the NTAP program is
to encourage early adoption of new and
clinically effective technology. The reimbursement, however, may also help to
avoid perverse incentives in the healthcare
system, in which clinically appropriate
transfers to comprehensive stroke centers
may be discouraged by either the receiving
or sending facilities, due to issues of
avoiding the cost of sicker patients or
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retaining the reimbursement of funded
patients.12
We have made great progress in our
ability to treat stroke and change lives.
Evidence of health benefits, however, do
not necessarily translate into evidence
of financial feasibility, and healthcare
systems may defer purchase of potentially
life-saving and cost-saving products until
the financial concerns have been alleviated. This decision represents a move by
CMS to remove some of those barriers.

Why this is a big deal for health care

CMS has previously proposed reimbursement for use of AI-enabled technology—
specifically automated retinal imaging—in
its 2021 Medicare physician fee schedule
proposed rule.13 This reimbursement
model addresses diagnostic applications
that perform functions analogous to those
otherwise performed by physicians, but
it is insufficient for novel uses, such as
parallel processing and triage.
CMS grappled with several of these
new concepts in its process of approving
Viz ContaCT for NTAP.1 It had to determine how to define cost for an application
with a subscription model—a common
payment model for software, but not for
physical tools. It had to understand how
it should consider the “novelty” of technology given AI’s capacity for learning and
improvement. It also had to consider the
value of technology to improve workflow,
going beyond the traditional paradigms
of straightforward diagnosis and treatment. Although healthcare AI tools and
companies have been in the headlines over
the past few years, healthcare has been
slower to adopt AI-powered applications
than other industries. Initial excitement
over proofs-of-concept and early progress
can quickly die without a viable financial
model to support further development
and deployment.
NTAP itself is unlikely to represent a
comprehensive solution for large-
scale
AI market success, given the inherent
limitations. It is a time-
limited decision
which is reviewed annually and expires
after 3 years, at which point the cost of
the technology may or may not be incorporated into the Medicare reimbursement
calculation, and the cost-
benefit considerations will change. The NTAP decision
specifies a single product as qualifying for
the additional payment, and CMS has to
determine whether this applies to other
products or not; to date, no other products have been deemed eligible by CMS.
Additionally, the NTAP requirement of
demonstrating novelty, high cost, and
improved clinical outcome represents a
2

barrier to acquire or even to attempt to
acquire such a designation.
That said, the fact that CMS has begun
to answer some of the questions of how
AI-powered tools can be incorporated into
reimbursement structures has illuminated
a possible pathway to a realistic healthcare
market for this technology.

CONCLUSION/TAKEAWAYS

In health care, doing the right thing for
patients unfortunately is not enough. In
order for new techniques, tools, and technology to be accepted and spread, they
have to be incentivized. This is a landmark decision, as it marks the beginning
of figuring out how we incentivize tools
that target what is often the most challenging part of health care—the workflow
issues that result from fragmented and
unoptimized systems. It’s a start to understanding how we might pay for advanced
technology like AI, so we can accelerate
adopting increasingly effective tools into
our practices. More specifically, it’s a win
for stroke care, and the patients who will
benefit from the treatment that we can
provide, now more efficiently.
Time will tell, but we may look back
and decide that this was the inflection
point, the beginning of a new age in acceptance of this technology into the healthcare mainstream.
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